ArticleGenes and immunity2008
Initial description of the human NLRP3 promoter.
Article in Genes and immunity, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- Post-translational modifications of NLRP3: to prime or not to prime?Trends in immunology · 2026Review
- The Role of Inflammasomes in Chronic Oral Inflammatory Disease and Oral Cancer: A Narrative Review.Dentistry journal · 2025Review
- Maternal Aspartame Exposure Induces Neonatal Pulmonary Metabolic Dysregulation and Redox Imbalance: A Multiomics Investigation of Gut Microbiota-Host Interactions.Journal of agricultural and food chemistry · 2025Article
- Background and Clinical Features of a Unique and Mysterious Autoinflammatory Disease, Schnitzler Syndrome.International journal of molecular sciences · 2025Review
- KLF feedback loops in innate immunity.Frontiers in immunology · 2025Review
- P2X7 receptors from the perspective of NLRP3 inflammasome pathway in depression: Potential role of cannabidiol.Brain, behavior, & immunity - health · 2024Article
- Article
- The discovery of NLRP3 and its function in cryopyrin-associated periodic syndromes and innate immunity.Immunological reviews · 2024Review
- Canonical and non-canonical functions of NLRP3.Journal of advanced research · 2023Review
- The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion.Cellular signalling · 2021Article
- Mechanisms of NLRP3 priming in inflammaging and age related diseases.Cytokine & growth factor reviews · 2020Review
- Toward targeting inflammasomes: insights into their regulation and activation.Cell research · 2020Review
- Corticosterone Inhibits LPS-Induced NLRP3 Inflammasome Priming in Macrophages by Suppressing Xanthine Oxidase.Mediators of inflammation · 2020Article
- Schnitzler's syndrome - a novel hypothesis of a shared pathophysiologic mechanism with Waldenström's disease.Orphanet journal of rare diseases · 2019Article
- [Genetics of cryopyrin-associated periodic syndrome].Zeitschrift fur Rheumatologie · 2017Review
- The kinase activity of PKR represses inflammasome activity.Cell research · 2016Article
- Role of genetic alterations in the NLRP3 and CARD8 genes in health and disease.Mediators of inflammation · 2015Review
- Xenobiotic pregnane X receptor (PXR) regulates innate immunity via activation of NLRP3 inflammasome in vascular endothelial cells.The Journal of biological chemistry · 2014Article
- Activation and regulation of the inflammasomes.Nature reviews. Immunology · 2013Review
- Glucocorticoids sensitize the innate immune system through regulation of the NLRP3 inflammasome.The Journal of biological chemistry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Mutations in NLRP3 (CIAS1) are identified in a continuum of related inflammatory disorders, known as cryopyrinopathies since NLRP3 codes for the protein cryopyrin. Approximately 40% of patients with classic presentation lack mutations in the coding region of NLRP3 suggesting heterogeneity or epigenetic factors. Cryopyrin is a key regulator of proinflammatory cytokine release. Therefore, variations in the NLRP3 promoter sequence may have effects on disease state in patients with cryopyrinopathies and other inflammatory diseases. In this report, we confirmed three 5'-untranslated region splice forms with two separate transcriptional start sites, and identified potential promoter regions and six new DNA promoter variants. One variant is unique to a mutation negative cryopyrinopathy patient and increases in vitro gene expression. Additional studies can now be performed to further characterize the NLRP3 promoter and sequence variants, which will lead to better understanding of the regulation of NLRP3 expression and its role in disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.